---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-345032"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2026-08-11T21:19:43+00:00"
generated_at: "2026-08-11T21:22:31.174135+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eloxx Q2 2026 net loss $4.5M; cash $62M; exaluren Phase 2b to start Q3 2026

## Summary
- Net loss of $4.5M ($0.39/share) for Q2 2026 vs $1.9M ($5.45/share) in Q2 2025; R&D spend up to $2.8M.
- Completed $66M public offering (2.975M shares at $11.00) plus pre-funded warrants; net proceeds $58.3M.
- Cash and equivalents $62.0M as of June 30, 2026; no debt; expected to fund into mid-2028.
- Phase 2b trial of exaluren in Alport syndrome expected to start Q3 2026; topline data mid-2027.
- EU granted orphan designation for exaluren in ADPKD; Phase 2 trial planned 2027.

## SEC filing metadata
- accession: 0001193125-26-345032
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2026-08-11T21:19:43+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/0001193125-26-345032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/d167833d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-345032
- JSON: https://secwatch.observer/filing/0001193125-26-345032.json
- Plain text: https://secwatch.observer/filing/0001193125-26-345032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.